

Management of COPD in Primary Care

Step 1	Symptom Management	1 Lifestyle Advice						
	<p>Start on Salbutamol MDI or Ipratropium MDI when required Review symptoms after 4 weeks (ask questions in panel 8). If not controlled move to Step 2. Remember to confirm diagnosis.</p>	<ul style="list-style-type: none"> Smoking cessation advice at every opportunity Dietary advice - If BMI < 18 or > 30 (For obesity grading I – III refer to dietician) Exercise – promote gentle exercise 						
Step 2	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; background-color: #e6f2ff;">FEV₁ ≥ 50% of predicted</td> <td style="width: 50%; background-color: #e6f2ff;">FEV₁ < 50% of predicted</td> </tr> <tr> <td style="background-color: #e6ffe6;"> <p>Add long acting therapy and review in 4 weeks</p> <p>OPTION 1</p> <p>Easyhaler® Formoterol One inhalation twice daily OR Atimos Modulite® One inhalation twice daily</p> <p>(Continue prn salbutamol or ipratropium)</p> <p>OPTION 2</p> <p>Tiotropium (Spiriva®) 1 inhalation daily <i>Only prescribe the device once and then put the capsules on repeat</i></p> <p>Plus prn salbutamol MDI <i>(Remember to stop the ipratropium)</i></p> <p>If no response at all, then switch to alternative option</p> </td> <td style="background-color: #ffffe6;"> <p>Add long acting therapy plus inhaled corticosteroid and review in 8 weeks</p> <p>OPTION 1</p> <p>Symbicort Turbohaler 400/12® (formoterol/budesonide) One inhalation twice daily*</p> <p>OR</p> <p>Seretide Accuhaler 500® (salmeterol/fluticasone) One inhalation twice daily*</p> <p>(Continue prn salbutamol or ipratropium)</p> <p>OPTION 2</p> <p>If inhaled corticosteroid is declined, add in Tiotropium Review in 4 weeks (If no benefit at all then stop this inhaler)</p> <p><small>*ONLY if patient is unable to use either device consider Seretide® 250 MDI 2 puffs twice daily via spacer – Evohaler® is unlicensed in COPD and 50% more expensive than licensed products.</small></p> </td> </tr> </table>	FEV₁ ≥ 50% of predicted	FEV₁ < 50% of predicted	<p>Add long acting therapy and review in 4 weeks</p> <p>OPTION 1</p> <p>Easyhaler® Formoterol One inhalation twice daily OR Atimos Modulite® One inhalation twice daily</p> <p>(Continue prn salbutamol or ipratropium)</p> <p>OPTION 2</p> <p>Tiotropium (Spiriva®) 1 inhalation daily <i>Only prescribe the device once and then put the capsules on repeat</i></p> <p>Plus prn salbutamol MDI <i>(Remember to stop the ipratropium)</i></p> <p>If no response at all, then switch to alternative option</p>	<p>Add long acting therapy plus inhaled corticosteroid and review in 8 weeks</p> <p>OPTION 1</p> <p>Symbicort Turbohaler 400/12® (formoterol/budesonide) One inhalation twice daily*</p> <p>OR</p> <p>Seretide Accuhaler 500® (salmeterol/fluticasone) One inhalation twice daily*</p> <p>(Continue prn salbutamol or ipratropium)</p> <p>OPTION 2</p> <p>If inhaled corticosteroid is declined, add in Tiotropium Review in 4 weeks (If no benefit at all then stop this inhaler)</p> <p><small>*ONLY if patient is unable to use either device consider Seretide® 250 MDI 2 puffs twice daily via spacer – Evohaler® is unlicensed in COPD and 50% more expensive than licensed products.</small></p>	2 Immunisation		
FEV₁ ≥ 50% of predicted	FEV₁ < 50% of predicted							
<p>Add long acting therapy and review in 4 weeks</p> <p>OPTION 1</p> <p>Easyhaler® Formoterol One inhalation twice daily OR Atimos Modulite® One inhalation twice daily</p> <p>(Continue prn salbutamol or ipratropium)</p> <p>OPTION 2</p> <p>Tiotropium (Spiriva®) 1 inhalation daily <i>Only prescribe the device once and then put the capsules on repeat</i></p> <p>Plus prn salbutamol MDI <i>(Remember to stop the ipratropium)</i></p> <p>If no response at all, then switch to alternative option</p>	<p>Add long acting therapy plus inhaled corticosteroid and review in 8 weeks</p> <p>OPTION 1</p> <p>Symbicort Turbohaler 400/12® (formoterol/budesonide) One inhalation twice daily*</p> <p>OR</p> <p>Seretide Accuhaler 500® (salmeterol/fluticasone) One inhalation twice daily*</p> <p>(Continue prn salbutamol or ipratropium)</p> <p>OPTION 2</p> <p>If inhaled corticosteroid is declined, add in Tiotropium Review in 4 weeks (If no benefit at all then stop this inhaler)</p> <p><small>*ONLY if patient is unable to use either device consider Seretide® 250 MDI 2 puffs twice daily via spacer – Evohaler® is unlicensed in COPD and 50% more expensive than licensed products.</small></p>							
		<p>Influenza, <i>annually</i> Pneumococcal. <i>as per green book</i></p>						
		3 Enhanced COPD Care Service						
		<p>Address social and Occupational Therapy issues</p>						
		4 Anxiety & Depression						
		<p>Screen for depression and anxiety and offer treatment</p>						
		5 Pulmonary Rehabilitation						
		<p>If MRC score is 3 or more refer to pulmonary rehabilitation</p>						
		6 Chronic productive cough						
		<p>Consider a 4 week trial of a mucolytic Carbocisteine 375mg - 2 capsules 3 times/day reducing to 2 capsules twice daily if good response. Continue only if symptomatic benefit. Do not use to prevent exacerbations.</p>						
Step 3	If still symptomatic, and diagnosis is confirmed	7 Oxygen Therapy						
	<p>Add in inhaled corticosteroid by switching to a combination inhaler – Symbicort® 400/12 or Seretide® 500 Accuhaler only. Review in 8 weeks</p> <p>If inhaled corticosteroid is declined or not appropriate, and patient not on Tiotropium, add in Tiotropium Review in 4 weeks (If no benefit at all then stop last inhaler)</p>	<p>For all patients if O₂ sats < 92% REFER to Primary Care Oxygen Service for Oxygen Assessment</p>						
	<p>Add to Option 1 a long acting muscarinic antagonist</p> <p>Tiotropium (Spiriva®) 1 inhalation daily <i>Only prescribe the device once and then put the capsules on repeat (Remember to stop the ipratropium)</i></p> <p>Review in 4 weeks (If no benefit at all then stop last inhaler)</p>	8 Assess treatment						
		<ul style="list-style-type: none"> Has the treatment made a difference to you? Is your breathing easier in any way? Has your sleep improved? Can you do some things that you could not do before or do the same things faster? Are you less breathless than before when doing things? Record MRC scale & BORG scale 						
Step 4	If still symptomatic							
	<p><input checked="" type="checkbox"/> Consider oral theophylline <input checked="" type="checkbox"/> In very severe COPD if oral corticosteroid (prednisolone 5mg tablets) treatment cannot be stopped after exacerbation, keep dose as low as possible. Monitor for osteoporosis & offer prophylaxis. If still symptomatic and severe consider:</p> <table style="width: 100%;"> <tr> <td><input checked="" type="checkbox"/> Consider pulmonary rehabilitation</td> <td><input checked="" type="checkbox"/> Referral to respiratory physician</td> </tr> <tr> <td><input checked="" type="checkbox"/> Consider nebuliser assessment</td> <td><input checked="" type="checkbox"/> Consider palliative care issues</td> </tr> <tr> <td><input checked="" type="checkbox"/> Consider referral for O₂ assessment</td> <td></td> </tr> </table>		<input checked="" type="checkbox"/> Consider pulmonary rehabilitation	<input checked="" type="checkbox"/> Referral to respiratory physician	<input checked="" type="checkbox"/> Consider nebuliser assessment	<input checked="" type="checkbox"/> Consider palliative care issues	<input checked="" type="checkbox"/> Consider referral for O ₂ assessment	
<input checked="" type="checkbox"/> Consider pulmonary rehabilitation	<input checked="" type="checkbox"/> Referral to respiratory physician							
<input checked="" type="checkbox"/> Consider nebuliser assessment	<input checked="" type="checkbox"/> Consider palliative care issues							
<input checked="" type="checkbox"/> Consider referral for O ₂ assessment								
	<p>Follow up: annual review for mild to moderate; at least 6mthly for severe and very severe Reviews to include spirometry. Ensure recall date is highlighted to patient and coded on system</p>							

Diagnosis

Consider

Consider diagnosis of COPD in any one > 35 and who is a smoker / ex smoker with the following symptoms:

- Chronic cough
- Breathlessness on exertion
- Regular sputum production
- Wheeze
- Frequent winter bronchitis
- No clinical features of asthma

Do post bronchodilatory Spirometry (absolute & % predicted)
Chest X-ray
Full blood count
BMI
Assess severity

Severity based on FEV₁ % of predicted

- Mild: >80%
- Moderate: 50 - 79 %
- Severe: 30 - 49 %
- Very Severe: <30%

For ALL people with COPD, ensure that the diagnosis is highlighted using active coding, and record spirometry

Exacerbations

Step 1 Are there any features to suggest hospital management?

- Severe breathlessness
- Cyanosis
- Worsening level of consciousness
- Acute confusion
- Receiving Long term oxygen therapy
- Worsening peripheral oedema
- Poor / deteriorating general condition
- Unable to cope at home/ lives alone
- Significant co morbidity e.g. CVD, diabetes
- Rapid onset of breathlessness O₂ sat < 90%

YES

Consider treatment in hospital

Step 2 ↑ Breathlessness

- Increase frequency of short acting bronchodilator MDI i.e. Salbutamol or Ipratropium via spacer
- Prednisolone tablets 30mg each morning for 7-14 days

Step 3 Purulent sputum production

1st line: Amoxicillin 500mg three times a day for 5 days (if allergic, Clarithromycin 500mg twice a day for 5 days)

2nd line: Doxycycline 200mg on 1st day then 100mg on days 2 - 5

Prophylactic antibiotics are NOT recommended

ACTION

- Give safety netting advice
- Optimise treatment
- Review patient if needed
- If more than 3 courses of oral steroids given in 1 year and over 65 consider assessing for osteoporosis risk

RESCUE MEDICATION RECOMMENDED: suitable patients should antibiotic and steroid stock in the house for use as per Clin. Man. Plan


Referral to specialist

When there is:

- Diagnostic uncertainty
- Uncontrolled severe COPD
- Onset of cor pulmonale
- Nebuliser assessment
- Assessment for surgery: bullous lung disease
- Rapid decline in FEV₁
- Aged < 40 or FH of alfa 1 antitrypsin deficiency
- Symptoms don't match lung function tests
- Frequent infection
- Haemoptysis

Fletcher and Peto Curve

Illustration of effects of smoking on rate of decline in FEV₁



Resources

NICE: www.nice.org.uk

Patient information leaflets: www.patient.co.uk

British Thoracic Society: www.brit-thoracic.org.uk

Green Book, can be found in Publications on www.dh.gov.uk

Antimicrobial Guidelines for Primary Care can be found on www.elmmb.nhs.uk

We would like to acknowledge Dr Tarek Bakht (Resp GPwSI), Bolton PCT, for his contribution in publication

GOLD: www.goldcopd.com

GP airways group: www.gpiag.org

Fletcher C, Peto R, Br Med J, 1:1645-1648, 1977